New CAR-T therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07543055
First seen Apr 23, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This early-stage study tests BPX-601, a CAR-T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has stopped responding to standard treatments. The main goals are to find safe doses and understand side effects. About 36 participants will receive the treatment to see if it can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.